Palvella Therapeutics Share Holder Equity 2014-2024 | PVLA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Palvella Therapeutics share holder equity from 2014 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Palvella Therapeutics share holder equity from 2014 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$139.4B
Gilead Sciences (GILD)	$114.7B
Bristol Myers Squibb (BMY)	$113.7B
Vertex Pharmaceuticals (VRTX)	$102.8B
CSL (CSLLY)	$85.4B
Regeneron Pharmaceuticals (REGN)	$77.2B
GSK (GSK)	$69.7B
Argenex SE (ARGX)	$37.4B
Alnylam Pharmaceuticals (ALNY)	$30.4B
BioNTech SE (BNTX)	$27B
Biogen (BIIB)	$21.9B
Illumina (ILMN)	$21.2B
BeiGene (BGNE)	$17.9B
Moderna (MRNA)	$15.2B
Genmab (GMAB)	$13.7B
Incyte (INCY)	$13.2B
BioMarin Pharmaceutical (BMRN)	$12.5B
Insmed (INSM)	$12.3B
Sarepta Therapeutics (SRPT)	$11.6B
Bio-Techne Corp (TECH)	$11.5B
Exact Sciences (EXAS)	$10.4B
Vaxcyte (PCVX)	$10.2B
QIAGEN (QGEN)	$10.2B
Swedish Orphan Biovitrum (BIOVF)	$9.8B
Exelixis (EXEL)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.1B
Intra-Cellular Therapies (ITCI)	$8.9B
Roivant Sciences (ROIV)	$8.3B
Ascendis Pharma (ASND)	$8.3B
Repligen (RGEN)	$8.1B